Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2011 May;10(5):645-58. doi: 10.1586/erv.11.28.

Tuberculosis vaccines in clinical trials.

Author information

  • 1The Jenner Institute, Old Road Campus Research Building, Oxford University, Oxford, OX3 7DQ, UK.

Abstract

Effective prophylactic and/or therapeutic vaccination is a key strategy for controlling the global TB epidemic. The partial effectiveness of the existing TB vaccine, bacille Calmette-Guérin (BCG), suggests effective vaccination is possible and highlights the need for an improved vaccination strategy. Clinical trials are evaluating both modifications to the existing BCG immunization methods and also novel TB vaccines, designed to replace or boost BCG. Candidate vaccines in clinical development include live mycobacterial vaccines designed to replace BCG, subunit vaccines designed to boost BCG and therapeutic vaccines designed as an adjunct to chemotherapy. There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen.

PMID:
21604985
[PubMed - indexed for MEDLINE]
PMCID:
PMC3409871
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk